Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 64 for “"anti-tumor immunity"”.
-
Complex N-Glycosylation in Anti-Tumor Immunity
… detection and a lack of effective treatments. Tumor-associated glycans represent a potential anti-tumor target for two reasons: (i) protein glycosylation is known to play a role in tumor progression, and (ii) alternatively glycosylated proteins may function as tumor neoantigens. The …
-
Re-Designing Cancer Immunotherapy to Enhance Anti-Tumor Immunity
… (MSC) based immunotherapy to study the immune tumor microenvironment (TME), and optimized radiotherapy delivery with cGAMP and systemic α-PD-L1 immunotherapies. Using MSC, we delivered various forms of anti-CD3 and/or co-signals to explore their contribution to re-activate T cells inside the …
-
The impact of intratumor heterogeneity on anti-tumor immunity
… cytotoxic CD8+ T cells, which recognize specific tumor cells and kill them. Specific recognition is bestowed by the presence of neoantigens, derived from mutated sequences arising during tumorigenesis. They are attractive targets because they are specific to tumor cells and have not been subjected …
-
Augmenting Anti-Tumor Immunity by Targeting Macrophage Cox-2 in Breast Cancer
… including breast. While the contributions of tumor cell-derived COX-2 are well studied, those of the stroma remain ill-defined. Macrophages, an essential component of the tumor microenvironment, exist within a range of two polar phenotypes, influenced by signals in their local environment: …
-
Immune Checkpoint Blockade Induces Gut Microbiota Translocation That Augments Extraintestinal Anti-Tumor Immunity
… by which gut microbiota augment extraintestinal anti-cancer immune responses, however, are largely unknown. Here, we find that ICT induces the translocation of specific endogenous gut microbiota into secondary lymphoid organs and subcutaneous melanoma tumors. Mechanistically, ICT induces lymph …
-
Priming systemic anti-tumor immunity via in situ immunomodulation of the tumor microenvironment
… immunotherapies including checkpoint blockade antibodies targeting the PD-1/PD-L1 axis and CTLA-4 have improved survival outcomes in a subset of cancer patients by driving tumor-directed immune responses. However, many patients do not benefit from such immunotherapies due to immune resistance …
-
THE CRITICAL ROLE OF CD4+ TH CELLS IN CD8+ CTL RESPONSES AND ANTI-TUMOR IMMUNITY
… called the “new dynamic model of CD4+ T helper – antigen (Ag)-presenting cells (Th-APCs),” proposed in 2005 by our laboratory. The study described in Chapter 2 shows that Th-APCs participate not only in augmenting CTL-mediated immune responses, perhaps during early phase, but also in regulating …
-
Elucidating the functional states of tumor-resident dendritic cells that drive productive anti-tumor immunity
… DC1, given their superior ability to initiate tumor-reactive cytotoxic CD8+ T cell responses. The exclusion or functional suppression of DC1 in tumors impedes CBT efficacy and enables tumor immune evasion and outgrowth. While the role of DC1 to anti-tumor immunity has been well-established, …
-
Coordinated Blockade of TGF-β and PD-L1 Promotes Anti-Tumor Immunity in Ovarian Cancer Models
… patients. This is due to an immunosuppressive tumor immune microenvironment (TIME) that limits the efficacy of ICB. Resistance to immunotherapy is driven in part by TGF-β signaling in the ovarian TIME, leading to immune suppression, metastasis, and development of malignant ascites. Bintrafusp …
-
A Novel Syndecan-1 Targeted Therapeutic Antibody Inhibits Macropinocytosis and Induces Anti-Tumor Immunity in Pancreatic Cancer
… multiple myeloma, while its potential in solid tumors is underestimated. More importantly, most of currently anti-SDC1 agents function by exploiting SDC1 as a surface target to deliver cytotoxic payload or facilitate immune cell-mediated killing, while the direct functional inhibition of SDC1 …
-
E3 Ubiquitin Ligase Cbl-b deficient T cells resist Treg cell-mediated suppression and enhance anti-tumor immunity
… system that contribute to the regulation of anti-tumor T cell responses. However, studies have suggested that alterations in T cell signaling networks can result in T cells that are resistant to the suppressive effects of Treg cells. Here, we specifically investigated the role of E3 ubiquitin …
-
Dendritic cell dysfunction restrains cytotoxic T cell responses against cancer
… respond. ICB acts by reinvigorating pre-existing anti-tumor immune responses, and responders are often characterized by the presence of a T cell infiltrate in tumors. However, T cell infiltration does not always correspond to ICB efficacy. Tumor-reactive T cells can acquire persistent …
-
Examining autoimmune sequelae during cancer immunotherapy in a combined autoimmune thyroiditis and tumor mouse model
… cancer patients, we developed a combined EAT and tumor model in our EAT-susceptible mice (CBA/J). In first establishing the tumor model, we found Treg depletion and irradiated tumor cell immunization necessary for robust anti-tumor immunity. We examined the anti-tumor induction model further and …
-
Regulation of the cGAS-STING Pathway: Non-Agonist Activation and Cellular Trafficking
… immunotherapy, STING agonists induce strong anti-tumor immunity in preclinical models and synergize with radiation, chemotherapy, and immune checkpoint inhibitor therapy. Evaluation of STING agonists in human clinical trials is ongoing, although early results did not yield satisfying …
-
Amphiphilic gold nanoparticle-based cytosolic drug delivery platform for cancer and infections
… One of the signature strategies utilized by tumor cells is immunosuppression. Deregulation of cytosolic kinases negatively alters immune cell signaling, proliferation, differentiation, and migration. Small molecule kinase inhibitors offer unique opportunities to enhance anti-tumor immunity by …
-
Tumor cell-immune cell interaction: A lethal two way street
… the role of Fas ligand in the development of anti-tumor immunity. The LSA tumor specific cytotoxic T lymphocyte (CTL) clone, PE-9, expressed both Fas and Fas ligand. This CTL clone upregulated Fas and Fas ligand expression upon activation through the T-cell receptor and induced apoptosis in …
-
Engaging Immune Cells within the Tumor Microenvironment to Enhance Efficacy of Oncolytic Virotherapy
… capacity to simultaneously cause direct lysis of tumor cells and indirect augmentation of host anti-tumor immunity. Despite widespread interest in the direct anti-cancer activity of oncolytic viruses, only limited attention has been paid to the interaction between viral therapy and the tumor …
-
Engineering more potent vaccines for the treatment of cancer and autoimmunity
… vaccines in the treatment of cancer and autoimmunity. Both major components of molecular vaccines, antigen and adjuvant, are independently explored as a part of this work. Our antigen studies sought to improve the delivery of peptide epitopes to lymphoid organs by fusing epitopes to inert …
-
ROLE OF IL-10 PRODUCING EOMES+ TR1-LIKE CELLS IN MELANOMA
… adaptive immune system’s ability to eradicate tumors are crucial for the development of effective cancer immunotherapies. In particular, the immunosuppressive functions of FOXP3+ T regulatory cells (Tregs) and EOMES+ type 1 regulatory T (Tr1) cells, which produce the anti-inflammatory cytokine …
Page 1 of 4